The present invention relates to a polypeptide having lipase activity wherein the polypeptide when aligned with the polypeptide according to SEQ ID NO: 1, comprises at least an amino acid substitution L410X and optionally one or more amino acid substitutions chosen from S365Q, S365N, L413M, G414A, G414S, G414V, G414T, V534L and V534l, wherein the 10 numbering of amino acid position(s) is/are defined with reference to SEQ ID NO: 1. The invention further relates to a process for preparing a product comprising an oil or fat comprising bringing an intermediary form of the product comprising oil or fat into contact with a polypeptide as disclosed herein and the use of a polypeptide as disclosed herein to saturated fatty acids in an oil or fat.

Preparation method and application of astaxanthin H1-, or H2- or J-aggregate water dispersion system are provided. The three kind of color-different astaxanthin multimer nano-dispersion systems utilize a special molecular structure of natural biomacromolecule chitosan and fish sperm DNA as well as physical interaction between macromolecules to induce formation and stability of astaxanthin multimers under solvent and salt ion-effects. Low-toxicity ethanol is selected as a good solvent for astaxanthin. The organic solvent can be completely removed in the later stage of the preparation process, and can be further enriched and recycled, which is beneficial to clean production and low cost. By adjusting process parameters, the H1-, or H2- or J-type astaxanthin aggregate water dispersion system can be obtained, so as to control a coloration range of astaxanthin water-based products to be yellow, orange and pink. Furthermore, during concentration, dehydration and reconstitution, astaxanthin aggregation patterns and coloring effects are maintained.

[PROBLEM] To provide a coenzyme Q production accelerator that allows increasing an intracellular coenzyme Q level.

[SOLUTION] The present invention is a coenzyme Q production accelerator containing nicotinamide mononucleotide as an active ingredient.

[PROBLEM] To provide a coenzyme Q production accelerator that allows increasing an intracellular coenzyme Q level.

[SOLUTION] The present invention is a coenzyme Q production accelerator containing nicotinamide mononucleotide as an active ingredient.

Provided are a xanthine amide hydrolase and the use thereof, particularly the use thereof for treating gout.

Provided are a xanthine amide hydrolase and the use thereof, particularly the use thereof for treating gout.

A nucleotide is useful in preparation of drugs for preventing and treating allergic rhinitis and other diseases or in functional foods for relieving allergic rhinitis symptoms. The nucleotide is a mixture of five nucleotides, i.e., CMP, AMP, UMP, GMP and IMP, with a small molecular weight, rapid absorption into the human body and high bioavailability. The intake of nucleotide can play a role of treating allergic diseases by alleviating allergic rhinitis symptoms, relieving allergy-induced splenomegaly, significantly reducing histamine levels in serum and nasal lavage fluid, and effectively regulating inflammatory factors.

The present invention relates to a pharmaceutical composition and the like for lowering blood cholesterol, preventing or treating cardiovascular diseases and reducing inflammation, containing, as an active ingredient, an inhibitor of binding between CAP1 and PCSK9, an inhibitor of binding between CAP1 and resistin, or a CAP1 gene expression inhibitor. The present invention can lower the level of blood LDL-cholesterol by inhibiting the binding of CAP1 and PCSK9, the binding of CAP1 and resistin or the expression of a CAP1 gene. Therefore, the present invention can be effectively used as a pharmaceutical composition and the like for treating abnormal blood cholesterol levels and various cardiovascular diseases caused thereby, such as dyslipidemia, stroke, arteriosclerosis, and the like, and for inhibiting inflammation.

The present invention relates to a melanogenesis detection method using FAM86A, and the like. The level of FAM86A of the present invention decreases according to an increase in the amount of melanin secretion or formation, and thus the present invention can whiten the skin by using protein FAM86A or an agonist thereof, and can prevent, treat or alleviate melanin-deficiency diseases such as vitiligo since the formation and secretion of melanin is promoted when FAM86A is inhibited. Therefore, the present invention is expected to be used in various ways, such as a composition for skin whitening using protein FAM86A or an agonist thereof, and as a composition for preventing and treating melanin deficiency diseases including vitiligo and canities by using a FAM86A inhibitor.

The present invention relates to a melanogenesis detection method using FAM86A, and the like. The level of FAM86A of the present invention decreases according to an increase in the amount of melanin secretion or formation, and thus the present invention can whiten the skin by using protein FAM86A or an agonist thereof, and can prevent, treat or alleviate melanin-deficiency diseases such as vitiligo since the formation and secretion of melanin is promoted when FAM86A is inhibited. Therefore, the present invention is expected to be used in various ways, such as a composition for skin whitening using protein FAM86A or an agonist thereof, and as a composition for preventing and treating melanin deficiency diseases including vitiligo and canities by using a FAM86A inhibitor.